Tag

Zealand Pharma

All articles tagged with #zealand pharma

biotech9 hours ago•3 min saved

Petrelintide Delivers Up to 10.7% Weight Loss in Zealand‑Roche Phase 2 Trial

Zealand Pharma's Roche-partnered amylin analog petrelintide achieved statistically significant weight loss versus placebo in a 493-person phase 2 obesity trial (Zupreme-1), with up to 10.7% mean weight reduction at 42 weeks and a tolerable safety profile (no vomiting at the maximally effective dose; mild GI adverse events); the results support moving toward phase 3 (Zupreme-2) and related combination studies, though some analysts question its potential impact in a crowded obesity market, and the stock fell on the news.

via Fierce Biotech|

#biotech #obesity #petrelintide

health1 year ago•2 min saved

Zealand Pharma Soars on Positive Weight-Loss Drug Trial Results

Zealand Pharma's stock rose 17% after announcing that its experimental weight loss drug petrelintide showed similar efficacy to Ozempic with fewer side effects in a phase 1 trial. Petrelintide, a long-acting amylin analog, could be an alternative for patients who can't tolerate GLP-1 treatments.

via Quartz|

#clinical-trial #glp-1 #health

businesshealth1 year ago•2 min saved

Zealand Pharma's Weight-Loss Drug Petrelintide Shows Promising Trial Results, Shares Surge 17%

Zealand Pharma's shares surged 18% after positive early-stage trial results for its weight loss drug petrelintide, which showed an average body weight reduction of 8.6% compared to 1.7% with a placebo. The drug was deemed safe and well-tolerated, positioning it as a potential alternative to GLP-1 receptor agonist-based therapies like Novo Nordisk's Ozempic. The company plans to proceed with a phase 2 clinical trial.

via CNBC|

#businesshealth #clinical-trial #petrelintide

health2 years ago•1 min saved

"Weight-Loss Drug Shows Promise in Treating Liver Disease in MASH Patients"

Boehringer Ingelheim and Zealand Pharma's drug, survodutide, has shown success in a Phase 2 study for the treatment of the liver condition MASH, with 83% of patients experiencing significant improvements compared to those who received a placebo. The study met its primary endpoint of improvements in MASH without the worsening of fibrosis, and secondary endpoints, including an improvement in fibrosis, were also achieved. This development comes amid increasing competition in the obesity medicine field.

via STAT|

#boehringer-ingelheim #health #liver-condition-mash

healthcare-and-pharmaceuticals2 years ago•2 min saved

"Rival Obesity Drugs Show Promising Results in Liver Disease Trials"

Zealand Pharma's stock surged 32% after positive trial results for its weight-loss drug, survodutide, which also showed efficacy in treating liver inflammation caused by excess fat cells. The drug has received fast-track designation from the FDA and is undergoing five Phase-3 trials for people who are overweight or obese, positioning the company as a key player in the highly lucrative obesity therapeutics market alongside competitors like Novo Nordisk and Eli Lilly.

via CNBC|

#eli-lilly #healthcare-and-pharmaceuticals #novo-nordisk